-$0.01 (-3.13%)
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Shawn M. Cross |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | AMTI |
| CUSIP | 03824M109 |
| CIK | 0001801777 |
| Web | https://www.appliedmt.com |
| Phone | 650 392 0420 |
| Currency | USD |
| Employees | 13 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.59 |
| Payout Ratio | 0.00 |
| Current Ratio | 4.24 |
| Quick Ratio | 4.24 |
| Cash Ratio | 4.05 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -2.52 |
| Price / Cash Flow | -0.11 |
| Price / Book | 0.17 |
Price Target and Rating
| Average Stock Price Forecast | $1.70 |
| High Stock Price Forecast | $3.00 |
| Low Stock Price Forecast | $0.40 |
| Forecast Upside/Downside | -84.53% |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 5 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-3.23 |
| Trailing P/E Ratio | -0.08 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $-125.43M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -111.78% |
| Return on Assets | -116.74% |
Financials Score
| AltmanZ Score | -39.20 |
| Piotroski Score | 2.00 |
| Working Capital | 15.04M |
| Total Assets | 20.02M |
| Ebit | -76.42M |
| Market Cap | 11.01M |
| Total Liabilities | 3.78M |
About Applied Molecular Transport Inc. (NASDAQ:AMTI) Stock
Applied Molecular Transport Inc. (AMTI), a biopharmaceutical company in the clinical development phase, was founded in 2010 and is based in South San Francisco, California. The firm is dedicated to discovering and advancing a pipeline of oral and respiratory biologic drug candidates, designed to address a variety of medical conditions including autoimmune, inflammatory, and metabolic diseases. Among its investigational treatments, AMT-101 stands out as the lead candidate. This orally administered, gastrointestinal (GI)-selective biologic, derived from rhIL-10, is presently in Phase II clinical trials for the management of ulcerative colitis and other related inflammatory indications. AMTI is also further developing AMT-126, another oral, GI-selective biologic that harnesses interleukin 22. ... This compound is currently undergoing Phase I clinical studies for the treatment of disorders stemming from impaired intestinal epithelial barrier function. The company's innovative technology platform allows for the creation and development of a broad spectrum of oral biologic therapeutic approaches, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid (RNA) therapeutics.
Frequently Asked Questions
What is the current Applied Molecular Transport Inc. (AMTI) stock price?
Applied Molecular Transport Inc.(NASDAQ:AMTI) stock price is $0.263 in the last trading session. During the trading session, AMTI stock reached the peak price of $0.84 while $0.1343 was the lowest point it dropped to. The percentage change in AMTI stock occurred in the recent session was --3.13% while the dollar amount for the price change in AMTI stock was -$-0.01.
AMTI's industry and sector of operation?
The NASDAQ listed AMTI is part of Biotechnology industry that operates in the broader Healthcare sector.
Who are the executives of AMTI?
Andrew H. Chang
| Head of Investor Relations & Corporation Communications
|
|
|
|
How many employees does AMTI have?
Number of AMTI employees currently stands at 13. AMTI operates from 450 East Jamie Court, South San Francisco, CA 94080, US.
Link for AMTI official website?
Official Website of AMTI is: https://www.appliedmt.com
How do I contact AMTI?
AMTI could be contacted at phone #650 392 0420 and can also be accessed through its website. AMTI operates from 450 East Jamie Court, South San Francisco, CA 94080, US.
How many shares of AMTI are traded daily?
The average number of AMTI shares traded daily for last 3 months was 316.86K.
What is the market cap of AMTI currently?
The market value of AMTI currently stands at $11.01M with its latest stock price at $0.263